Cheymol G, Poirier J M
Service de Pharmacologie, Hôpital Saint-Antoine, Paris.
Therapie. 1992 Jul-Aug;47(4):289-92.
The therapeutic use of cyclosporine (CsA) requires total blood levels to be monitored with a specific assay, since this drug is nephrotoxic, has a narrow therapeutic index, shows wide intra- and inter-individual differences in its pharmacokinetic behaviour and can interact with other drugs. The parameter generally measured is the residual blood concentration at equilibrium; levels are occasionally again measured four or six hours after CsA administration. Patients are monitored every two days during the first two weeks following organ transplantation, a frequency which gradually declines to monthly determinations at four to six months in the absence of complications. The therapeutic range of blood CsA concentrations is still poorly defined. In renal, liver, heart and bone marrow transplantation most authors recommend concentrations of 100-250 ng/ml for the first three months when renal function is satisfactory. Ways of administration (i.e. continuous infusion or dividing up of the daily dose) must be taken into consideration to assess values of blood concentration of CsA.
环孢素（CsA）的治疗应用需要通过特定检测方法监测全血水平，因为这种药物具有肾毒性、治疗指数窄、药代动力学行为存在较大个体内和个体间差异且会与其他药物相互作用。通常测定的参数是平衡时的残余血药浓度；偶尔也会在给予CsA四或六小时后再次测定血药浓度。在器官移植后的头两周内，每两天对患者进行监测，若无并发症，该频率会逐渐降至四至六个月时每月测定一次。血液中CsA浓度的治疗范围仍界定不清。在肾、肝、心和骨髓移植中，大多数作者建议在肾功能良好的头三个月，CsA浓度维持在100 - 250 ng/ml。评估CsA血药浓度值时必须考虑给药方式（即持续输注或分剂量给药）。
